Form 8-K - Current report:
SEC Accession No. 0001193125-20-003049
Filing Date
2020-01-07
Accepted
2020-01-07 16:21:03
Documents
12
Period of Report
2020-01-07
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K d842477d8k.htm   iXBRL 8-K 27179
  Complete submission text file 0001193125-20-003049.txt   146199

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA apls-20200107.xsd EX-101.SCH 3066
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20200107_lab.xml EX-101.LAB 17373
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20200107_pre.xml EX-101.PRE 10950
11 EXTRACTED XBRL INSTANCE DOCUMENT d842477d8k_htm.xml XML 3208
Mailing Address 6400 WESTWIND WAY SUITE A CRESTWOOD KY 40014
Business Address 6400 WESTWIND WAY SUITE A CRESTWOOD KY 40014 502-241-4114
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 20513538
SIC: 2834 Pharmaceutical Preparations